Lumos Pharma (NASDAQ:LUMO) Given Buy Rating at HC Wainwright

Lumos Pharma (NASDAQ:LUMO)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They currently have a $28.00 price target on the stock.

Separately, Oppenheimer reduced their price objective on Lumos Pharma from $17.00 to $16.00 and set an “outperform” rating on the stock in a research report on Monday, December 11th.

Lumos Pharma Stock Performance

NASDAQ:LUMO opened at $2.90 on Wednesday. Lumos Pharma has a 52-week low of $2.51 and a 52-week high of $4.55. The firm has a market cap of $23.52 million, a price-to-earnings ratio of -0.69 and a beta of 0.67. The business’s fifty day moving average is $2.96 and its 200 day moving average is $3.19.

Lumos Pharma (NASDAQ:LUMO) last released its quarterly earnings data on Thursday, March 7th. The company reported ($1.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.01. The company had revenue of $0.83 million for the quarter, compared to analyst estimates of $0.01 million. Lumos Pharma had a negative return on equity of 85.63% and a negative net margin of 1,659.39%. During the same period in the previous year, the company posted ($0.98) EPS. Equities analysts predict that Lumos Pharma will post -2.8 EPS for the current fiscal year.

Institutional Investors Weigh In On Lumos Pharma

Institutional investors have recently bought and sold shares of the stock. Greenwich Wealth Management LLC boosted its holdings in Lumos Pharma by 55.8% during the 3rd quarter. Greenwich Wealth Management LLC now owns 76,341 shares of the company’s stock valued at $252,000 after acquiring an additional 27,339 shares during the period. Private Advisor Group LLC boosted its holdings in Lumos Pharma by 42.8% during the 3rd quarter. Private Advisor Group LLC now owns 20,013 shares of the company’s stock valued at $66,000 after acquiring an additional 6,000 shares during the period. Vanguard Group Inc. boosted its holdings in Lumos Pharma by 3.7% during the 4th quarter. Vanguard Group Inc. now owns 244,082 shares of the company’s stock valued at $776,000 after acquiring an additional 8,645 shares during the period. Jefferies Financial Group Inc. purchased a new stake in Lumos Pharma during the 4th quarter valued at about $436,000. Finally, Shay Capital LLC purchased a new stake in Lumos Pharma during the 4th quarter valued at about $180,000. 35.23% of the stock is currently owned by hedge funds and other institutional investors.

About Lumos Pharma

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.